- Home
- ADX vs IBRX Comparison
ADX vs IBRX Comparison
Compare ADX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADX
- IBRX
- Stock Information
- Founded
- ADX 1840
- IBRX 2014
- Country
- ADX United States
- IBRX United States
- Employees
- ADX N/A
- IBRX N/A
- Industry
- ADX Investment Managers
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADX Finance
- IBRX Health Care
- Exchange
- ADX Nasdaq
- IBRX Nasdaq
- Market Cap
- ADX 2.3B
- IBRX 2.6B
- IPO Year
- ADX N/A
- IBRX N/A
- Fundamental
- Price
- ADX $18.61
- IBRX $2.92
- Analyst Decision
- ADX
- IBRX Strong Buy
- Analyst Count
- ADX 0
- IBRX 4
- Target Price
- ADX N/A
- IBRX $12.19
- AVG Volume (30 Days)
- ADX 182.4K
- IBRX 6.4M
- Earning Date
- ADX 01-01-0001
- IBRX 03-03-2025
- Dividend Yield
- ADX 6.68%
- IBRX N/A
- EPS Growth
- ADX N/A
- IBRX N/A
- EPS
- ADX N/A
- IBRX N/A
- Revenue
- ADX N/A
- IBRX $14,745,000.00
- Revenue This Year
- ADX N/A
- IBRX $753.44
- Revenue Next Year
- ADX N/A
- IBRX $174.29
- P/E Ratio
- ADX N/A
- IBRX N/A
- Revenue Growth
- ADX N/A
- IBRX 2270.58
- 52 Week Low
- ADX $14.94
- IBRX $2.28
- 52 Week High
- ADX $19.57
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- ADX 28.63
- IBRX 44.03
- Support Level
- ADX $18.63
- IBRX $2.73
- Resistance Level
- ADX $19.79
- IBRX $3.16
- Average True Range (ATR)
- ADX 0.40
- IBRX 0.27
- MACD
- ADX -0.15
- IBRX -0.04
- Stochastic Oscillator
- ADX 9.17
- IBRX 16.19
About ADX Adams Diversified Equity Fund Inc.
Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally-managed closed-end fund. The investment objectives of the company are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It has a diversified equity portfolio which consists of securities of companies from Energy, Consumer Staples, Information Technology, Financials and other sectors.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.